Research programme: neutralising antibody therapeutics - ImmunoPrecise Antibodies
Alternative Names: 23-H7; Antibodies for Coronavirus - ImmunoPrecise Antibodies; antibody 23-H7; Multi-antibody cocktail therapy; neutralizing antibodies for COVID-19 - ImmunoPrecise Antibodies; PolyTopeTM mAbLatest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator ImmunoPrecise Antibodies; Talem Therapeutics
- Developer ImmunoPrecise Antibodies
- Class Antivirals; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in USA (Parenteral)
- 28 Sep 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (Parenteral)
- 25 Mar 2021 Pharmacodynamics data from a preclinical studies in COVID-2019 infections released by ImmunoPrecise Antibodies